Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | CCR9 | P51686 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20657752 | 0.84 | TP53 (0.64) | TP53LMNASMN1; SMN2ALDH1A1CCR9 | |
| SCHEMBL11533596 | 0.77 | LMNA (0.57) | TP53LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4781525 | 0.74 | ALDH1A1 (1.00) | TP53LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17779217 | 0.72 | MAPT (0.59) | TP53LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17774618 | 0.72 | MAPT (0.65) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL4782068 | 0.72 | ALDH1A1 (0.83) | TP53LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL23355082 | 0.72 | MCOLN3 (0.70) | TP53LMNAALDH1A1KMT2ABRPF1 | |
| SCHEMBL15652359 | 0.70 | MAPT (0.58) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL17774670 | 0.70 | MAPT (0.79) | LMNASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL5252021 | 0.70 | ALDH1A1 (0.72) | TP53LMNASMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3438091-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | AJINOMOTO CO., INC. (JP) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129458-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | TP53 4210/4885LMNA 3342/4885SMN1; SMN2 3136/4885 |
| US-20190022039-A1 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS | GLP1R, GPR119, GIPR | TP53 4210/4885LMNA 3342/4885SMN1; SMN2 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.